A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: FEC|DRUG: Docetaxel|DRUG: TCH
Sponsor: Hoffmann-La Roche